Onychomycosis

Clinics in Dermatology

Volumn 28, Issue 2, 2010, Pages 151-159

  Welsh, Oliverio ^a   Vera Cabrera, Lucio ^a   Welsh, Esperanza ^b  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b Centro de Especialidades Médicas   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE DERIVATIVE; AMOROLFINE; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; BENZYLAMINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUTENAFINE; CICLOPIROXOLAMINE; CIMETIDINE; CYCLOSPORIN; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; MONOAMINE OXIDASE B INHIBITOR; NAFTIFINE; PHENYTOIN; PLACEBO; POSACONAZOLE; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; RAVUCONAZOLE; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; TERBINAFINE; TIOCONAZOLE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ANTIFUNGAL RESISTANCE; CANDIDA; CANDIDIASIS; CLINICAL FEATURE; DERMATOLOGICAL PROCEDURES; DERMATOMYCOSIS; DERMATOPHYTE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; EPIDERMOPHYTON FLOCCOSUM; ERYTHEMA; ERYTHEMA MULTIFORME; FALSE NEGATIVE RESULT; FINGERNAIL ONYCHOMYCOSIS; FLUSHING; FUNGAL STRAIN; FUNGUS CULTURE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; HYPOGLYCEMIA; LIVER FUNCTION TEST; LIVER TOXICITY; LUPUS VULGARIS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MOULD; MYCOSIS; NAUSEA; NONHUMAN; NOTE; ONYCHOMYCOSIS; PERIODIC ACID SCHIFF STAIN; PERIPHERAL EDEMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; SEPSIS; SIDE EFFECT; SKIN DISEASE; SYSTEMIC DISEASE; TASTE DISORDER; TOENAIL ONYCHOMYCOSIS; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; URTICARIA; VISUAL DISORDER; VOMITING; YEAST;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FLUCONAZOLE; FOOT DERMATOSES; HUMANS; ITRACONAZOLE; MITOSPORIC FUNGI; MORPHOLINES; NAPHTHALENES; ONYCHOMYCOSIS; PYRIDONES; PYRIMIDINES; THIAZOLES; TRIAZOLES;

EID: 77950282875     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2009.12.006     Document Type: Note

References (48)

1. Elewski B., Charif M. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997, 133:1172-1173.
2. Elewski B. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998, 11:415-429.
3. Faergemann J., Correia O., Nowicki R., Ro B.I. Genetic predisposition-understanding underlying mechanisms of onychomycosis. J Eur Acad Dermatol Venereol 2005, 19(Suppl 1):17-19.
4. Heikkilä H., Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995, 133:699-703.
5. Lateur N., Mortaki A., André J. Two hundred ninety-six cases of onychomycosis in children and teenagers: a 10-year laboratory survey. Pediatr Dermatol 2003, 20:385-388.
6. Effendy I., Lecha M., Feuilhade de Chauvin M., Di Chiacchio N., Baran R. European Onychomycosis Observatory. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol 2005, 19(Suppl 1):8-12.
7. Hay R. Literature review. Onychomycosis. J Eur Acad Dermatol Venereol 2005, 19(Suppl 1):1-7.
8. Welsh O., Welsh E., Ocampo-Candiani J., Gomez M., Vera-Cabrera L. Dermatophytoses in Monterrey, México. Mycoses 2006, 49:119-123.
9. Seebacher C., Bouchara J.P., Mignon B. Updates on the epidemiology of dermatophyte infections. Mycopathologia 2008 2008, 166:335-352.
10. Kaur R., Kashyap B., Bhalla P. Onychomycosis-epidemiology, diagnosis and management. Indian J Med Microbiol 2008, 26:108-116.
11. Gupta A.K., Ryder J.E., Summerbell R.C. Onychomycosis: classification and diagnosis. J Drugs Dermatol 2004, 3:51-56.
12. Tosti A., Piraccini B.M., Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 2000, 42:217-224.
13. Gupta A.K., Ricci M.J. Diagnosing onychomycosis. Dermatol Clin 2006, 24:365-369.
14. Arca E., Saracli M.A., Akar A., Yildiran S.T., Kurumlu Z., Gur A.R. Polymerase chain reaction in the diagnosis of onychomycosis. Eur J Dermatol 2004, 14:52-55.
15. Weinberg J.M., Koestenblatt E.K., Tutrone W.D., Tishler H.R., Najarian L. Comparison of diagnostic methods in the evaluation of onychomycosis. J Am Acad Dermatol 2003, 49:193-197.
16. Shemer A., Davidovici B., Grunwald M.H., Trau H., Amichai B. Comparative study of nail sampling techniques in onychomycosis. J Dermatolog Treat 2009, 36:410-414.
17. Shemer A., Davidovici B., Grunwald M.H., Trau H., Amichai B. New criteria for the laboratory diagnosis of nondermatophyte moulds in onychomycosis. Br J Dermatol 2008-2009, 160:37-39.
18. Piérard G.E., Quatresooz P., Arrese J.E. Spotlight on nail histomycology. Dermatol Clin 2006, 24:371-374.
19. Szepietowski J.C., Reich A., Garlowska E., Kulig M., Baran E. Onychomycosis Epidemiology Study Group. Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. Arch Dermatol 2006, 142:1279-1284.
20. Cathcart S., Cantrell W., Elewski B. Onychomycosis and diabetes. J Eur Acad Dermatol Venereol 2009, 23:1119-1122.
21. Baran R., Hay R.J., Garduno J. Review of antifungal therapy and the severity index for assessing onychomycosis: part I. J Dermatolog Treat 2008, 19:72-81.
22. Baran R., Hay R.J., Garduno J. Review of antifungal therapy, part II: treatment rationale, including specific patient populations. J Dermatolog Treat 2008, 19:168-175.
23. Kumar S., Kimball A.B. New antifungal therapies for the treatment of onychomycosis. Expert Opin Investig Drugs 2009, 18:727-734.
24. Nair A.B., Kim H.D., Chakraborty B., et al. Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J Pharm Sci 2009, 98:4130-4140.
25. Baran R., Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005, 19:21-29.
26. Watanabe D., Kawamura C., Masuda Y., Akita Y., Tamada Y., Matsumoto Y. Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol 2008, 144:19-21.
27. Piraccini B.M., Rech G., Tosti A. Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 2008, 59(5 Suppl):S75-76.
28. Huang P.H., Paller A.S. Itraconazole pulse therapy for dermatophyte onychomycosis in children. Arch Pediatr Adolesc Med 2000, 154:614-618.
29. Gupta A.K., Cooper E.A., Montero-Gei F. The use of fluconazole to treat superficial fungal infections in children. Dermatol Clin 2003, 21:537-542.
30. Sethi A., Antaya R. Systemic antifungal therapy for cutaneous infections in children. Pediatr Infect Dis J 2006, 25:643-644.
31. Gupta A.K., Cooper E.A. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008, 166:353-367.
32. Gupta A.K., Cooper E.A., Ginter G. Efficacy and safety of itraconazole use in children. Dermatol Clin 2003, 21:521-535.
33. Tosti A., Piraccini B.M., Lorizzo M. Management of onychomycosis in children. Dermatol Clin 2003, 21:507-509. [vii].
34. Bonifaz A., Ibarra G. Onychomycosis in children: treatment with bifonazole-urea. Pediatr Dermatol 2000, 17:310-314.
35. Suarez S., Friedlander S.F. Antifungal therapy in children: an update. Pediatr Ann 1998, 27:177-184.
36. Gupta A.K., Ryder J.E., Lynch L.E., Tavakkol A. The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. J Drugs Dermatol 2005, 302-308.
37. Pasqualotto A.C., Denning D.W. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008, 61(Suppl 1):i19-i30.
38. Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 2009, 18:1279-1295.
39. Gonzalez G.M., Elizondo M., Ayala J. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. J Clin Microbiol 2008, 46:2902-2905.
40. Gupta A.K., Leonardi C., Stoltz R.R., Pierce P.F., Conetta B. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 2005, 19:437-443.
41. Geria A.N., Scheinfeld N.S. Pramiconazole, a triazole compound for the treatment of fungal infections. IDrugs 2008, 11:661-670.
42. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol 2001, 145(Suppl 60):21-26.
43. Sergeev Y., Sergeev A. Pulsed combination therapy: a new option for onychomycosis. Mycoses 2001, 44(Suppl 1):68-69.
44. Gupta A.K., Lynde C.W., Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol 2001, 44:485-491.
45. Polak A. Preclinical data and mode of action of amorolfine. Dermatology 1992, 184(Suppl 1):3-7.
46. Gupta A.K., Schouten J.R., Lynch L.E. Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective. Skin Therapy Lett 2005, 10:1-3.
47. Barak O., Loo D.S. A novel antifungal for the topical treatment of onychomycosis. Curr Opin Investig Drugs 2007, 8:662-668.
48. Scher R.K., Tavakkol A., Sigurgeirsson B., et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 2007, 56:939-944.